Edition:
India

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

121.75USD
11:29pm IST
Change (% chg)

$1.28 (+1.06%)
Prev Close
$120.47
Open
$119.46
Day's High
$122.10
Day's Low
$119.43
Volume
193,854
Avg. Vol
714,780
52-wk High
$149.17
52-wk Low
$96.18

Select another date:

Thu, Feb 8 2018

BRIEF-Alexion Pharma Q4 GAAP Earnings Per Share $0.13

* ALEXION REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND PROVIDES FINANCIAL GUIDANCE FOR 2018

Alexion, Elliott to jointly look for new director

Jan 2 Alexion Pharmaceuticals Inc said on Tuesday it had agreed to work with hedge fund Elliott Management to identify a new member to join the drugmaker's board.

BRIEF-Alexion And Elliott Agree To Collaborate On Identifying A New Board Member

* ALEXION AND ELLIOTT AGREE TO COLLABORATE ON IDENTIFYING A NEW BOARD MEMBER

UPDATE 2-Elliott Management seeks changes at Alexion - NYT

Dec 8 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

CORRECTED-Elliott Management seeks changes at Alexion - NYT (Dec. 7)

Dec 7 U.S. hedge fund Elliott Management, which has built a stake in Alexion Pharmaceuticals, is urging the company to take more action to boost its stock price, including exploring a sale, the New York Times reported on Thursday.

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

BRIEF-Alexion receives new Japanese patent for Soliris

* Alexion receives new Japanese patent for Soliris® (eculizumab), extending patent protection into 2027 and strengthening global patent portfolio Source text for Eikon: Further company coverage:

BRIEF-Alexion reports Q3 non-GAAP earnings per share of $1.44

* Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

Select another date: